Frontiers in Psychiatry,
Journal Year:
2024,
Volume and Issue:
15
Published: Oct. 30, 2024
Psilocybin,
a
psychoactive
substance,
has
recently
garnered
attention
for
its
high
therapeutic
potential
in
psychiatry.
In
this
study,
we
investigated
the
multifaceted
aspects
of
psilocybin,
highlighting
chemical
properties,
mechanisms
action,
and
burgeoning
role
psychiatric
treatment.
Furthermore,
examined
clinical
applications
benefits
psilocybin
treatment
various
mental
health
disorders,
supported
by
accumulating
evidence.
This
review
aims
to
deepen
our
understanding
impact
elucidate
value,
propose
directions
future
research,
thereby
paving
way
integration
into
mainstream
treatments.
Psilocybin
been
shown
be
safe
trials
with
manageable
side
effects.
However,
additional
safety
measures
are
required
after
discussion,
including
dosing
protocols,
patient
monitoring,
distress
management
strategies.
Frontiers in Neuroscience,
Journal Year:
2024,
Volume and Issue:
18
Published: July 10, 2024
Alzheimer’s
disease
(AD)
stands
as
a
formidable
neurodegenerative
ailment
and
prominent
contributor
to
dementia.
The
scarcity
of
available
therapies
for
AD
accentuates
the
exigency
innovative
treatment
modalities.
Psilocybin,
psychoactive
alkaloid
intrinsic
hallucinogenic
mushrooms,
has
garnered
attention
within
neuropsychiatric
realm
due
its
established
safety
efficacy
in
treating
depression.
Nonetheless,
potential
therapeutic
avenue
remains
largely
uncharted.
This
comprehensive
review
endeavors
encapsulate
pharmacological
effects
psilocybin
while
elucidating
existing
evidence
concerning
mechanisms
contributing
positive
impact
on
AD.
Specifically,
active
metabolite
psilocybin,
psilocin,
elicits
through
modulation
5-hydroxytryptamine
2A
receptor
(5-HT2A
receptor).
causes
heightened
neural
plasticity,
diminished
inflammation,
improvements
cognitive
functions
such
creativity,
flexibility,
emotional
facial
recognition.
Noteworthy
is
psilocybin’s
promising
role
mitigating
anxiety
depression
symptoms
patients.
Acknowledging
attendant
adverse
reactions,
we
proffer
strategies
aimed
at
tempering
or
effects.
Moreover,
broach
ethical
legal
dimensions
inherent
exploration
treatment.
By
traversing
these
avenues,
We
propose
nuanced
management
disease.
Journal of Psychopharmacology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 12, 2025
Background:
Migraine
and
cluster
headache
are
two
primary
disorders
for
which
conventional
treatments
limited.
Classic
psychedelic
substances
such
as
lysergic
acid
diethylamide
(LSD)
psilocybin
potentially
promising
new
treatment
candidates
these
conditions.
Aims:
The
aim
of
the
present
study
was
to
investigate
possible
relationship
between
lifetime
use
classic
psychedelics
frequent
bad
headaches
in
a
large
British
cohort
sample.
Methods:
Using
data
(
N
=
11,419)
collected
1999–2000
part
1958
National
Child
Development
Study,
this
cross-sectional
used
multiple
logistic
regression,
controlling
range
potential
confounders,
test
hypothesis
that
would
be
associated
with
lower
odds
having
headaches.
Results:
Lifetime
25%
(adjusted
ratio
0.75,
95%
CI:
0.59–0.95,
p
0.016).
Conclusions:
results
add
literature
suggesting
future
prophylactic
option
disorders.
Frontiers in Pain Research,
Journal Year:
2025,
Volume and Issue:
6
Published: March 18, 2025
Fibromyalgia
(FM)
is
the
prototypical
nociplastic
pain
condition,
characterized
by
widespread
and
issues
with
cognition,
mood,
sleep.
Currently,
there
are
limited
treatment
options
available
that
effectively
treat
FM
symptoms.
Psilocybin-assisted
therapy
(PAT)
an
emerging
combined
drug-therapy
intervention,
but
no
studies
to-date
have
investigated
PAT
for
FM.
Here,
we
report
findings
from
open-label,
pilot
clinical
trial
of
(N
=
5).
In
conjunction
psychotherapy
(two
preparatory,
four
integration
sessions),
participants
received
two
doses
oral
psilocybin
(15
mg
25
mg)
delivered
weeks
apart.
Regarding
safety
(primary
outcome),
were
transient
elevations
blood
pressure
or
heart
rate
during
dosing
which
normalized
end
treatment,
serious
adverse
events.
Four
five
reported
headaches
following
dosing.
Compared
to
baseline,
clinically
meaningful
improvements
in
secondary
outcomes
one
month
their
second
dose
(reported
as
Cohen's
d):
severity
[d
-2.1,
95%
CI(-3.7
-0.49)],
interference
-1.8,
CI
(-3.27
-0.24)],
sleep
disturbance
-2.5,
(-4.21
-0.75)].
Using
Patient
Global
Impression
Change,
participant
symptoms
"very
much
improved,"
"much
"minimally
improved."
We
stopped
recruitment
early
because
concerns
about
generalizability
changes
FDA
guidance
psychedelic
trials
occurred
data
collection.
This
small
open-label
preliminarily
supports
well-tolerated
people
FM,
establishing
a
basis
larger
randomized
controlled
trials.
ClinicalTrials.gov,
identifier,
(NCT05128162).
Cancers,
Journal Year:
2024,
Volume and Issue:
16(9), P. 1702 - 1702
Published: April 27, 2024
Despite
the
legalization
of
psilocybin
therapy
for
depression
in
terminal
illnesses
such
as
advanced
cancer
through
Oregon’s
Measure
109
2020,
significant
challenges
have
impeded
its
implementation.
This
review
synthesizes
empirical
data
supporting
utilization
addressing
cancer-related
depression,
including
an
evaluation
purported
benefits
and
potential
adverse
effects.
It
provides
a
comprehensive
examination
therapeutic
strategies,
dosing
regimens,
barriers
to
ensuring
responsible
equitable
access.
Salient
issues
explored
include
development
ethical
protocols,
integration
within
healthcare
systems,
statewide
availability,
resolving
legal
ambiguities,
defining
clinical
standards.
pioneering
role
serves
case
study,
highlighting
necessity
regulatory,
logistical,
obstacles
ensure
establishment
rigorous
care
models.
Brain Sciences,
Journal Year:
2024,
Volume and Issue:
14(4), P. 348 - 348
Published: March 31, 2024
Background:
Cluster
headache
(CH)
is
a
debilitating
condition,
but
current
therapies
leave
CH
patients
in
pain.
The
extent
of
this
problem
Sweden
unknown.
Methods:
An
anonymized
questionnaire
was
sent
to
479
Swedish
investigate
patterns
and
perceived
effects
treatments.
Results:
Three
hundred
fourteen
answers
were
analyzed.
population
representative
regarding
age
onset
sex.
Less
than
half
(46%)
satisfied
with
their
abortive
treatments,
19%
terminated
functioning
treatments
due
side
effects.
Additionally,
17%
chronic
had
not
tried
the
first-line
preventive
drug
verapamil.
A
small
subset
illicit
substances
treat
(0–8%
depending
on
substance).
Notably,
psilocybin
reported
effective
as
an
treatment
by
100%
(n
=
8),
some
level
effect
92%
12).
For
verapamil,
among
68%
85).
Conclusions:
Our
descriptive
data
illustrate
that
many
are
undertreated,
lack
functional
therapies,
experience
Further
studies
warranted
search
for
new
strategies
well
revision
guidelines
aim
reducing
patient
disease
burden
greatest
possible.
Journal of Chromatography A,
Journal Year:
2024,
Volume and Issue:
1730, P. 465123 - 465123
Published: July 4, 2024
Psilocybin
is
a
psychedelic
compound
found
in
some
hallucinogenic
"magic
mushrooms".
Psilocin
the
active
metabolite
of
Psilocybin,
and
it
subject
several
studies
for
treatment
psychological
disorders,
such
as
anxiety,
depression,
post-traumatic
stress
disorder.
As
such,
pharmacokinetic
properties
psilocin
should
be
evaluated
to
ensure
its
safety
efficacy
part
drug
development
process.
Based
on
previously
published
studies,
reversed-phase
liquid
chromatography
(LC)
was
tested
quantification.
The
analysis,
however,
showed
major
interference
mouse
plasma
that
not,
best
our
knowledge,
reported
previously.
We,
therefore,
aimed
identify
separate
interference,
using
various
chromatographic
columns,
mobile
phase
conditions,
mass
spectrometers
(MS)
instruments.
Chromatographic
separation
achieved
an
ultra
high
performance
(UHPLC)
system,
quadrupole-linear
ion
trap
equipped
with
electrospray
ionization
(ESI)
source
used
positive
mode
multiple
reaction
monitoring
(MRM).
Several
conditions
column
chemistries,
including
C-18
Phenyl-hexyl
were
initially
tested,
failed
interference.
Exact
measurement
MS/MS
analysis
determine
structure
interfering
compound,
which
confirmed
tryptophan.
Using
identified
fast
reliable
hydrophilic
interaction
(HILIC)-MS/MS
method
developed
validated,
capable
separating
from
while
achieving
0.5
ng/ml
lower
limit
quantification
(LLOQ).
validated
successfully
applied
study
where
orally
administered
C57BL/6
subjects.
concentration
all
analyzed
samples
determined.
